Clinical trials
Severe Combined Immunodeficiency clinical trials
Below are recruiting severe combined immunodeficiency clinical trials, each written for real people, not researchers. We’re tracking 15 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03601286RecruitingPhase 1
Gene therapy for X-linked SCID using a modified virus
This early-stage study tests a one-time lentiviral gene therapy to help children with X-linked severe combined immunodeficiency (SCID-X1) make infection-fighting T cells. It may reduce the need for a matching donor transplant, but it requires long-term follow-up for safety over many years.
London, Greater LondonAges 2 months–5 years - NCT05071222RecruitingPhase 1/Phase 2
Gene therapy trial for Artemis SCID using modified blood cells
This trial tests whether gene therapy can safely and effectively treat children with a specific type of severe combined immunodeficiency (SCID) caused by an Artemis gene problem. It uses the patient’s own stem cells, modifies them to add a missing gene, and then returns them after chemotherapy to help the new cells work.
ParisAges Up to 3.9 years - NCT06659588Recruiting
Study of chronic hepatitis risk in people with immune weaknesses
This study looks at people with certain immune system weaknesses to see if they are at risk for chronic hepatitis caused by a virus in the gut. Researchers want to understand how the immune system affects this infection.
ParisAges Any age - NCT00055172Recruiting
Understanding Genetic Causes of Immune System Disorders
This research study investigates why some people have weak or poorly functioning immune systems. By studying you and your relatives, researchers hope to identify genetic factors that cause these conditions and eventually develop better treatments.
Bethesda, MarylandAges 6 months–99 years - NCT01306019RecruitingPhase 1/Phase 2
Gene therapy for children with severe immune deficiency (XSCID)
This trial tests a one-time gene therapy approach to help children with X-linked SCID (a serious inherited immune disorder) make better immune cells. It’s for people who don’t have a fully matched sibling donor and need long-term follow-up after treatment.
Bethesda, MarylandAges 2–50 - NCT01852370Enrolling by invitationPhase 1/Phase 2
Lung and bone marrow transplant plan for immune system disorders
This early-phase study tests a step-by-step transplant approach: first replacing the lungs, then doing a bone marrow (stem cell) transplant to treat certain immune deficiency diseases. It may help people whose immune problem has led to severe, end-stage lung disease.
Pittsburgh, PennsylvaniaAges 5–45 - NCT06851767Enrolling by invitationPhase 1/Phase 2
Gene therapy for X-linked severe combined immunodeficiency
This trial tests a gene therapy that uses base-edited stem cells to treat X-SCID, a genetic immune disorder. It may help improve immune function and reduce infections in patients who still have low immune cells or severe infections despite previous treatments.
Bethesda, MarylandAges 3–99 - NCT03311503RecruitingPhase 1/Phase 2
Gene therapy for X-linked SCID in young children
This trial tests a gene therapy using a lentivirus to give missing immune system instructions in children with X-linked SCID (SCID-X1). It also uses a low dose of targeted chemotherapy (busulfan) to help the new genes work, and it requires long-term follow-up for safety.
Los Angeles, CaliforniaAges birth–5 years - NCT03538899RecruitingPhase 1/Phase 2
Gene therapy for children with an Artemis SCID immune problem
This early-phase study tests an “autologous” gene therapy, meaning they use the child’s own cells, adjusted with a working gene, to help restore immune function. It is for babies and children with Artemis-deficient SCID, aiming to improve T-cell immunity and reduce the need for lifelong infection risk management.
San Francisco, CaliforniaAges 2 months+ - NCT05651113Recruiting
Your experience during screening for SCID
This study looks at what it feels like for people to go through screening for SCID (a rare immune condition). It may help improve the screening process and support for patients and families.
LondonAges 18 years+ - NCT01186913Enrolling by invitation
Natural history study for severe combined immune deficiency (SCID)
This study follows children and adults with SCID and related immune disorders to understand how the illness behaves over time. It also helps researchers learn which testing results and genetic types of SCID match different treatment plans.
Birmingham, AlabamaAges Any age - NCT04049084Enrolling by invitation
Follow-up study for people treated with gene therapy for ADA-SCID
This is a follow-up (no new treatment) study for people who previously received a gene therapy made from their own cells for ADA-SCID. It mainly tracks long-term safety and whether a marker showing the gene change can still be found.
Los Angeles, CaliforniaAges Any age - NCT03478670Enrolling by invitation
Registry follow-up for ADA-SCID patients treated with Strimvelis
This study keeps track of people with ADA-SCID (a rare immune system condition) who previously received Strimvelis or a related treatment. It helps doctors understand long-term outcomes and safety after treatment.
Milan, LombardyAges Any age - NCT06205056RecruitingPhase 1
HIV vaccine safety and immune response test
This trial tests a new combination HIV vaccine in healthy adults to see if it is safe and produces an immune response. If you are at low risk for HIV, you may help researchers learn more about future prevention strategies.
KampalaAges 18–50 - NCT06453317RecruitingPhase 2
Comparing UC treatments: infliximab vs ustekinumab vs both
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
LodzAges 18–64
Hear when a new Severe Combined Immunodeficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for severe combined immunodeficiency?
- Yes. Clin2 currently lists 15 recruiting severe combined immunodeficiency studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a severe combined immunodeficiency trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a severe combined immunodeficiency trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.